Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Involvement of CDK11B-mediated SPDEF ubiquitination and SPDEF-mediated microRNA-448 activation in the oncogenicity and self-renewal of hepatocellular carcinoma stem cells

Abstract

Increasing evidence has suggested the crucial role cyclin-dependent kinases (CDKs) in the biology of hepatocellular carcinoma (HCC), a lethal malignancy with high morbidity and mortality. Hence, this study explored the modulatory effect of the putative cyclin-dependent kinase 11B (CDK11B)-mediated ubiquitination on HCC stem cells. The expression of CDK11B, SAM pointed domain-containing ETS transcription factor (SPDEF) and DOT1-like histone lysine methyltransferase (DOT1L) was determined by RT-qPCR and western blot analysis in HCC tissues and cells. The interaction among CDK11B, SPDEF, miR-448, and DOT1L was analyzed by Co-IP, ubiquitination-IP and ChIP assays, whereas their effects on the biological characteristics of HCC stem cells were assessed by sphere formation and colony formation assays. An in vivo xenograft tumor model was developed for validating the regulation of CDK11B in oncogenicity of HCC stem cells. We characterized the aberrant upregulation of CDK11B and downregulation SPDEF in HCC tissues and cells. CDK11B degraded SPDEF through ubiquitin-proteasome pathway, whereas SPDEF could bind to the miR-448 promoter and inhibit the expression of DOT1L by activating miR-448, whereby promoting self-renewal of HCC stem cells. Knockdown of CDK11B attenuated the self-renewal capability of HCC stem cells and their oncogenicity in vivo. These findings highlighted that blocking the CDK11B-induced degradation of SPDEF and enhancing miR-448-dependent inhibition of DOT1L may delay the progression of HCC by restraining self-renewal capability of HCC stem cells, representing novel targets for HCC management.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1: CDK11B is highly expressed in HCC and its knockdown reduces the proliferation of HCC cells.
Fig. 2: CDK11B suppresses the expression of SPDEF by promoting SPDEF phosphorylation and ubiquitination.
Fig. 3: SPDEF inhibits DOT1L expression by activating miR-448 transcription.
Fig. 4: The self-renewal of HCC SMMC-7721 stem cells was inhibited by SPDEF through downregulation of DOT1L repression.
Fig. 5: The involvement of the CDK11B/SPDEF/miR-448/DOT1L axis in the oncogenicity and self-renewal property of HCC stem cells in vivo.
Fig. 6: A schematic for the CDK11B/SPDEF/miR-448/DOT1L axis in the progression of HCC.

References

  1. Shimada S, Mogushi K, Akiyama Y, Furuyama T, Watanabe S, Ogura T, et al. Comprehensive molecular and immunological characterization of hepatocellular carcinoma. EBioMedicine 2019;40:457–70.

    Article  Google Scholar 

  2. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391:1301–14.

    Article  Google Scholar 

  3. Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology 2019;156:477–91. e1.

    Article  Google Scholar 

  4. Santopaolo F, Lenci I, Milana M, Manzia TM, Baiocchi L. Liver transplantation for hepatocellular carcinoma: where do we stand? World J Gastroenterol. 2019;25:2591–602.

    Article  Google Scholar 

  5. Liao Y, Feng Y, Shen J, Hornicek FJ, Duan Z. The roles and therapeutic potential of cyclin-dependent kinases (CDKs) in sarcoma. Cancer Metastasis Rev. 2016;35:151–63.

    Article  CAS  Google Scholar 

  6. Shen S, Dean DC, Yu Z, Duan Z. Role of cyclin-dependent kinases (CDKs) in hepatocellular carcinoma: therapeutic potential of targeting the CDK signaling pathway. Hepatol Res. 2019;49:1097–108.

    Article  CAS  Google Scholar 

  7. Alonso MH, Ausso S, Lopez-Doriga A, Cordero D, Guino E, Sole X, et al. Comprehensive analysis of copy number aberrations in microsatellite stable colon cancer in view of stromal component. Br J Cancer. 2017;117:421–31.

    Article  CAS  Google Scholar 

  8. Tamura RE, Paccez JD, Duncan KC, Morale MG, Simabuco FM, Dillon S, et al. GADD45alpha and gamma interaction with CDK11p58 regulates SPDEF protein stability and SPDEF-mediated effects on cancer cell migration. Oncotarget 2016;7:13865–79.

    Article  Google Scholar 

  9. Meiners J, Schulz K, Moller K, Hoflmayer D, Burdelski C, Hube-Magg C, et al. Upregulation of SPDEF is associated with poor prognosis in prostate cancer. Oncol Lett. 2019;18:5107–18.

    CAS  PubMed  PubMed Central  Google Scholar 

  10. Wu J, Qin W, Wang Y, Sadik A, Liu J, Wang Y, et al. SPDEF is overexpressed in gastric cancer and triggers cell proliferation by forming a positive regulation loop with FoxM1. J Cell Biochem. 2018;119:9042–54.

    Article  CAS  Google Scholar 

  11. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. Annu Rev Pathol. 2014;9:287–314.

    Article  Google Scholar 

  12. Zhu H, Zhou X, Ma C, Chang H, Li H, Liu F, et al. Low expression of miR-448 induces EMT and promotes invasion by regulating ROCK2 in hepatocellular carcinoma. Cell Physiol Biochem. 2015;36:487–98.

    Article  CAS  Google Scholar 

  13. Guo JC, Yang YJ, Zhang JQ, Guo M, Xiang L, Yu SF, et al. microRNA-448 inhibits stemness maintenance and self-renewal of hepatocellular carcinoma stem cells through the MAGEA6-mediated AMPK signaling pathway. J Cell Physiol. 2019;234:23461–74.

    Article  CAS  Google Scholar 

  14. Gibbons GS, Chakraborty A, Grigsby SM, Umeano AC, Liao C, Moukha-Chafiq O, et al. Identification of DOT1L inhibitors by structure-based virtual screening adapted from a nucleoside-focused library. Eur J Med Chem. 2020;189:112023.

    Article  CAS  Google Scholar 

  15. Lv L, Li Q, Chen S, Zhang X, Tao X, Tang X, et al. miR-133b suppresses colorectal cancer cell stemness and chemoresistance by targeting methyltransferase DOT1L. Exp Cell Res. 2019;385:111597.

    Article  CAS  Google Scholar 

  16. Reish NJ, Maltare A, McKeown AS, Laszczyk AM, Kraft TW, Gross AK, et al. The age-regulating protein klotho is vital to sustain retinal function. Invest Ophthalmol Vis Sci. 2013;54:6675–85.

    Article  CAS  Google Scholar 

  17. Chen EB, Zhou SL, Pang XG, Yin D, Miao PZ, Yang Y, et al. Prostate-derived ETS factor improves prognosis and represses proliferation and invasion in hepatocellular carcinoma. Oncotarget 2017;8:52488–500.

    Article  Google Scholar 

  18. Shao YY, Li YS, Hsu HW, Lin H, Wang HY, Wo RR, et al. Potent activity of composite cyclin dependent kinase inhibition against hepatocellular carcinoma. Cancers (Basel). 2019;11:1433.

  19. Haider C, Grubinger M, Reznickova E, Weiss TS, Rotheneder H, Miklos W, et al. Novel inhibitors of cyclin-dependent kinases combat hepatocellular carcinoma without inducing chemoresistance. Mol Cancer Ther. 2013;12:1947–57.

    Article  CAS  Google Scholar 

  20. Ehrlich SM, Liebl J, Ardelt MA, Lehr T, De Toni EN, Mayr D, et al. Targeting cyclin dependent kinase 5 in hepatocellular carcinoma–a novel therapeutic approach. J Hepatol. 2015;63:102–13.

    Article  CAS  Google Scholar 

  21. Yin T, Liu MM, Jin RT, Kong J, Wang SH, Sun WB. miR-152-3p Modulates hepatic carcinogenesis by targeting cyclin-dependent kinase 8. Pathol Res Pract. 2019;215:152406.

    Article  CAS  Google Scholar 

  22. Liu TH, Wu YF, Dong XL, Pan CX, Du GY, Yang JG, et al. Identification and characterization of the BmCyclin L1-BmCDK11A/B complex in relation to cell cycle regulation. Cell Cycle. 2017;16:861–8.

    Article  CAS  Google Scholar 

  23. Xiao B, Kuang Z, Zhang W, Hang J, Chen L, Lei T, et al. Glutamate ionotropic receptor kainate type subunit 3 (GRIK3) promotes epithelial-mesenchymal transition in breast cancer cells by regulating SPDEF/CDH1 signaling. Mol Carcinog. 2019;58:1314–23.

    Article  CAS  Google Scholar 

  24. Lo YH, Noah TK, Chen MS, Zou W, Borras E, Vilar E, et al. SPDEF induces quiescence of colorectal cancer cells by changing the transcriptional targets of beta-catenin. Gastroenterology 2017;153:205–18. e8.

    Article  CAS  Google Scholar 

  25. Motti ML, S DA, Meccariello R. MicroRNAs, cancer and diet: facts and new exciting perspectives. Curr Mol Pharm. 2018;11:90–6.

    Article  CAS  Google Scholar 

  26. Qi H, Wang H, Pang D. miR-448 promotes progression of non-small-cell lung cancer via targeting SIRT1. Exp Ther Med. 2019;18:1907–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Lou Q, Liu R, Yang X, Li W, Huang L, Wei L, et al. miR-448 targets IDO1 and regulates CD8(+) T cell response in human colon cancer. J Immunother Cancer. 2019;7:210.

    Article  Google Scholar 

  28. Ivey KN, Srivastava D. microRNAs as developmental regulators. Cold Spring Harb Perspect Biol. 2015;7:a008144.

    Article  Google Scholar 

  29. Yang L, Lei Q, Li L, Yang J, Dong Z, Cui H. Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer. Clin Epigenetics. 2019;11:199.

    Article  CAS  Google Scholar 

  30. Sarno F, Nebbioso A, Altucci L. DOT1L: a key target in normal chromatin remodelling and in mixed-lineage leukaemia treatment. Epigenetics. 2019;15:439–53.

  31. Bourguignon LY, Wong G, Shiina M. Up-regulation of histone methyltransferase, DOT1L, by matrix hyaluronan promotes MicroRNA-10 expression leading to tumor cell invasion and chemoresistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem. 2016;291:10571–85.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We acknowledge and appreciate our colleagues for their valuable suggestions and technical assistance for this study. This work was supported by the Key Research and Development Plan of Hainan Province (2019RC373) and Hainan Natural Science Foundation (818MS161).

Author information

Authors and Affiliations

Authors

Contributions

Jun-cheng Guo and Yi-jun Yang designed the study. Min Guo, Jian-quan Zhang, and Jin-fang Zheng collated the data, carried out data analyses and produced the initial draft of the manuscript. Zhuo Liu contributed to drafting the manuscript. All authors have read and approved the final submitted manuscript.

Corresponding authors

Correspondence to Yi-jun Yang or Jian-quan Zhang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Guo, Jc., Yang, Yj., Guo, M. et al. Involvement of CDK11B-mediated SPDEF ubiquitination and SPDEF-mediated microRNA-448 activation in the oncogenicity and self-renewal of hepatocellular carcinoma stem cells. Cancer Gene Ther 28, 1136–1149 (2021). https://doi.org/10.1038/s41417-020-00261-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41417-020-00261-w

Search

Quick links